Association Between CD133, CD44, and Nestin Expression and Prognostic Factors in High-Grade Meningioma

Dai Kamamoto, Isako Saga, Kentaro Ohara, Kazunari Yoshida, Hikaru Sasaki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Meningioma is the most common primary brain tumor. It is graded as I, II, or III based on the World Health Organization (WHO) classification of central nervous system tumors. Meningiomas, especially those classified as grade II–III, have an aggressive history and a high recurrence rate. Cancer stem cells (CSCs) represent a small subset of tumor cells and are considered to be involved in tumor initiation, growth, and/or recurrence. To date, the CSCs of meningioma have not been well established. Methods: We assessed 51 grade II/III meningiomas using immunohistochemistry to determine if a correlation exists with the prognosis by investigating CD133, CD44, and nestin expression as possible CSC markers and age, gender, initial WHO tumor grade, Simpson grade, and the use of adjuvant radiation therapy. Results: The median overall survival was 7.1 years, and the median progression-free survival (PFS) was 1.8 years. Univariate analysis using Cox proportional hazards regression revealed a negative correlation between CD133 and nestin expression and PFS (P = 0.0176 and P = 0.0138, respectively), and high expression of CD44 demonstrated a tendency toward a shorter PFS (P = 0.0563), as did the initial WHO grade and Simpson grade found at the initial operation (P = 0.0166 and P 0.0333, respectively). Multivariate analysis showed relevance between CD133 and nestin expression and PFS. Conclusions: CD133 and nestin expression, initial WHO grade and Simpson grade were associated with PFS in patients with grade II/III meningioma. These findings might suggest that these molecules are representative of CSCs in meningioma regarding the aspect of clinical course.

Original languageEnglish
JournalWorld Neurosurgery
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Nestin
Meningioma
Neoplastic Stem Cells
Disease-Free Survival
Recurrence
Central Nervous System Neoplasms
Neoplasms
Brain Neoplasms
Radiotherapy
Multivariate Analysis
History
Immunohistochemistry
Survival
Growth

Keywords

  • Cancer stem cells
  • CD133
  • CD44
  • High-grade meningioma
  • Nestin
  • Prognosis
  • Simpson grade

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Association Between CD133, CD44, and Nestin Expression and Prognostic Factors in High-Grade Meningioma. / Kamamoto, Dai; Saga, Isako; Ohara, Kentaro; Yoshida, Kazunari; Sasaki, Hikaru.

In: World Neurosurgery, 01.01.2019.

Research output: Contribution to journalArticle

@article{0f777dbaff304c3e8c0c5684a4eb617c,
title = "Association Between CD133, CD44, and Nestin Expression and Prognostic Factors in High-Grade Meningioma",
abstract = "Background: Meningioma is the most common primary brain tumor. It is graded as I, II, or III based on the World Health Organization (WHO) classification of central nervous system tumors. Meningiomas, especially those classified as grade II–III, have an aggressive history and a high recurrence rate. Cancer stem cells (CSCs) represent a small subset of tumor cells and are considered to be involved in tumor initiation, growth, and/or recurrence. To date, the CSCs of meningioma have not been well established. Methods: We assessed 51 grade II/III meningiomas using immunohistochemistry to determine if a correlation exists with the prognosis by investigating CD133, CD44, and nestin expression as possible CSC markers and age, gender, initial WHO tumor grade, Simpson grade, and the use of adjuvant radiation therapy. Results: The median overall survival was 7.1 years, and the median progression-free survival (PFS) was 1.8 years. Univariate analysis using Cox proportional hazards regression revealed a negative correlation between CD133 and nestin expression and PFS (P = 0.0176 and P = 0.0138, respectively), and high expression of CD44 demonstrated a tendency toward a shorter PFS (P = 0.0563), as did the initial WHO grade and Simpson grade found at the initial operation (P = 0.0166 and P 0.0333, respectively). Multivariate analysis showed relevance between CD133 and nestin expression and PFS. Conclusions: CD133 and nestin expression, initial WHO grade and Simpson grade were associated with PFS in patients with grade II/III meningioma. These findings might suggest that these molecules are representative of CSCs in meningioma regarding the aspect of clinical course.",
keywords = "Cancer stem cells, CD133, CD44, High-grade meningioma, Nestin, Prognosis, Simpson grade",
author = "Dai Kamamoto and Isako Saga and Kentaro Ohara and Kazunari Yoshida and Hikaru Sasaki",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.wneu.2018.12.067",
language = "English",
journal = "World Neurosurgery",
issn = "1878-8750",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Association Between CD133, CD44, and Nestin Expression and Prognostic Factors in High-Grade Meningioma

AU - Kamamoto, Dai

AU - Saga, Isako

AU - Ohara, Kentaro

AU - Yoshida, Kazunari

AU - Sasaki, Hikaru

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Meningioma is the most common primary brain tumor. It is graded as I, II, or III based on the World Health Organization (WHO) classification of central nervous system tumors. Meningiomas, especially those classified as grade II–III, have an aggressive history and a high recurrence rate. Cancer stem cells (CSCs) represent a small subset of tumor cells and are considered to be involved in tumor initiation, growth, and/or recurrence. To date, the CSCs of meningioma have not been well established. Methods: We assessed 51 grade II/III meningiomas using immunohistochemistry to determine if a correlation exists with the prognosis by investigating CD133, CD44, and nestin expression as possible CSC markers and age, gender, initial WHO tumor grade, Simpson grade, and the use of adjuvant radiation therapy. Results: The median overall survival was 7.1 years, and the median progression-free survival (PFS) was 1.8 years. Univariate analysis using Cox proportional hazards regression revealed a negative correlation between CD133 and nestin expression and PFS (P = 0.0176 and P = 0.0138, respectively), and high expression of CD44 demonstrated a tendency toward a shorter PFS (P = 0.0563), as did the initial WHO grade and Simpson grade found at the initial operation (P = 0.0166 and P 0.0333, respectively). Multivariate analysis showed relevance between CD133 and nestin expression and PFS. Conclusions: CD133 and nestin expression, initial WHO grade and Simpson grade were associated with PFS in patients with grade II/III meningioma. These findings might suggest that these molecules are representative of CSCs in meningioma regarding the aspect of clinical course.

AB - Background: Meningioma is the most common primary brain tumor. It is graded as I, II, or III based on the World Health Organization (WHO) classification of central nervous system tumors. Meningiomas, especially those classified as grade II–III, have an aggressive history and a high recurrence rate. Cancer stem cells (CSCs) represent a small subset of tumor cells and are considered to be involved in tumor initiation, growth, and/or recurrence. To date, the CSCs of meningioma have not been well established. Methods: We assessed 51 grade II/III meningiomas using immunohistochemistry to determine if a correlation exists with the prognosis by investigating CD133, CD44, and nestin expression as possible CSC markers and age, gender, initial WHO tumor grade, Simpson grade, and the use of adjuvant radiation therapy. Results: The median overall survival was 7.1 years, and the median progression-free survival (PFS) was 1.8 years. Univariate analysis using Cox proportional hazards regression revealed a negative correlation between CD133 and nestin expression and PFS (P = 0.0176 and P = 0.0138, respectively), and high expression of CD44 demonstrated a tendency toward a shorter PFS (P = 0.0563), as did the initial WHO grade and Simpson grade found at the initial operation (P = 0.0166 and P 0.0333, respectively). Multivariate analysis showed relevance between CD133 and nestin expression and PFS. Conclusions: CD133 and nestin expression, initial WHO grade and Simpson grade were associated with PFS in patients with grade II/III meningioma. These findings might suggest that these molecules are representative of CSCs in meningioma regarding the aspect of clinical course.

KW - Cancer stem cells

KW - CD133

KW - CD44

KW - High-grade meningioma

KW - Nestin

KW - Prognosis

KW - Simpson grade

UR - http://www.scopus.com/inward/record.url?scp=85060168852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060168852&partnerID=8YFLogxK

U2 - 10.1016/j.wneu.2018.12.067

DO - 10.1016/j.wneu.2018.12.067

M3 - Article

AN - SCOPUS:85060168852

JO - World Neurosurgery

JF - World Neurosurgery

SN - 1878-8750

ER -